UK pharma seeks reasons to be cheerful

As senior figures from the UK biopharma industry gathered in a gloomy London for the Annual Conference of The Association of the British Pharmaceutical Industry (ABPI), many speakers and panellists showed a stoic positivity despite the myriad of challenges engulfing the sector.

As well as the broader budgetary constraints facing the National Health Service (NHS) and their inevitable impact on the UK’s ability to pay for medicines, the sector is facing a number of challenges that bring into question the government’s ambition set out in the 2021 Life Sciences Vision, seeking to create a global superpower in the field.

The VPAS priority